Pronutria Biosciences Inc., a Cambridge, MA-based biotechnology company advancing medicines for serious conditions linked to amino acid imbalances, completed a $42.5m funding round.
The round was led by Nestlé Health Science, a wholly-owned subsidiary of Nestlé. In conjunction with the funding, Greg Behar, Nestlé Health Science CEO, will join the Pronutria board of directors.
The company intends to use the funds to advance late stage clinical candidates in several disease indications.
Led by Robert Connelly, President and CEO, and Dr. Noubar Afeyan, co-founder and Chairman (and CEO of Flagship Ventures), Pronutria is advancing medicines to treat or cure serious conditions where cell homeostasis has been disrupted by amino acid imbalances. The company aims to achieve its target by using a systems pharmacology approach to deliver disease-specific amino acid compositions that improve the function of biological pathways and regenerate health. They are now developing the first oral biologics, derived from the food proteome, that deliver disease-specific amino acid compositions to restore balance in disease pathways, regenerating cell function.
Pronutria’s platform is already validated across several indication areas with clinical-stage medicines in muscle, neurodegenerative and liver conditions and the company is developing both therapeutics and nutritional supplements.
Founded within VentureLabs, the Innovation Foundry at Flagship Ventures, Pronutria received additional funding from Fidelity Research & Management Group and Gurnet Point Capital.